These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7379058)
1. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058 [TBL] [Abstract][Full Text] [Related]
2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
3. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Weiss AJ; Metter GE; Fletcher WS; Wilson WL; Grage TB; Ramirez G Cancer Treat Rep; 1976 Jul; 60(7):813-22. PubMed ID: 795537 [TBL] [Abstract][Full Text] [Related]
4. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Wheeler RH; Ensminger WD; Thrall JH; Anderson JL Cancer Treat Rep; 1982 Mar; 66(3):493-8. PubMed ID: 7060037 [TBL] [Abstract][Full Text] [Related]
5. A phase of I trial of 4'-epi-Adriamycin. Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract. Martino S; Samal B; Al-Sarraf M Cancer Treat Rep; 1980 Jan; 64(1):161-3. PubMed ID: 7379051 [TBL] [Abstract][Full Text] [Related]
7. [Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancy]. Takagi T; Oguro M; Iwabuchi K Gan To Kagaku Ryoho; 1984 Jul; 11(7):1450-6. PubMed ID: 6588924 [TBL] [Abstract][Full Text] [Related]
8. [A phase I study of 4'-epi-adriamycin, a new anthracycline anticancer agent]. Kimura K; Wakui A; Saito T; Tominaga T; Niitani H; Fujimoto T; Masaoka T; Toki H; Tamura K Gan To Kagaku Ryoho; 1984 Nov; 11(11):2414-9. PubMed ID: 6594078 [TBL] [Abstract][Full Text] [Related]
9. Noninvasive monitoring of adriamycin cardiotoxicity by "Sphygmo-Recording" of the pulse wave delay (QKd interval). Greco FA; Brereton HD; Rodbard D Cancer Treat Rep; 1976 Sep; 60(9):1239-45. PubMed ID: 797446 [TBL] [Abstract][Full Text] [Related]
10. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases]. Wang SQ Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):71-3. PubMed ID: 1889343 [TBL] [Abstract][Full Text] [Related]
12. Adriamycin cardiotoxicity: a survey of 1273 patients. Praga C; Beretta G; Vigo PL; Lenaz GR; Pollini C; Bonadonna G; Canetta R; Castellani R; Villa E; Gallagher CG; von Melchner H; Hayat M; Ribaud P; De Wasch G; Mattsson W; Heinz R; Waldner R; Kolaric K; Buehner R; Ten Bokkel-Huyninck W; Perevodchikova NI; Manziuk LA; Senn HJ; Mayr AC Cancer Treat Rep; 1979 May; 63(5):827-34. PubMed ID: 455324 [TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
14. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
15. [Phase II study of (2''R)-4'-O-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Multi-Institutional Cooperative Study]. Saito T; Kasai Y; Wakui A; Furue H; Majima H; Nitani H; Niijima T; Takeda C; Abe O; Koyama Y Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1060-9. PubMed ID: 3963850 [TBL] [Abstract][Full Text] [Related]
16. [Phase II study of KRN8602 (MX2) for malignant lymphoma]. Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314 [TBL] [Abstract][Full Text] [Related]
17. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422 [TBL] [Abstract][Full Text] [Related]
18. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]
19. [Preliminary phase II clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM)]. Majima H Gan To Kagaku Ryoho; 1983 Mar; 10(3):805-10. PubMed ID: 6882000 [TBL] [Abstract][Full Text] [Related]
20. [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]